Induction of receptor for advanced glycation end products by EBV latent membrane protein 1 and Its correlation with angiogenesis and cervical lymph node metastasis in nasopharyngeal carcinoma

Clinical Cancer Research

Volumn 14, Issue 17, 2008, Pages 5368-5375

  Tsuji, Akira ^a   Wakisaka, Naohiro ^a   Kondo, Satoru ^a   Murono, Shigeyuki ^a   Furukawa, Mitsuru ^a   Yoshizaki, Tomokazu ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; LUCIFERASE; PROTEIN S 100; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; IMMUNOGLOBULIN RECEPTOR; MATRIX PROTEIN;

ANGIOGENESIS; ARTICLE; BINDING SITE; CANCER CLASSIFICATION; CERVICAL LYMPH NODE; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MICROVASCULATURE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; WESTERN BLOTTING; GENETICS; METABOLISM; NASOPHARYNX TUMOR; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; TRANSACTIVATION; TUMOR CELL LINE; VASCULARIZATION;

CELL LINE, TUMOR; HUMANS; LYMPHATIC METASTASIS; NASOPHARYNGEAL NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROMOTER REGIONS (GENETICS); RECEPTORS, IMMUNOLOGIC; S100 PROTEINS; TRANS-ACTIVATION (GENETICS); VIRAL MATRIX PROTEINS;

EID: 53049087445     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0198     Document Type: Article

References (38)

1. Cassisi NJ. Tumors of the pharynx. In: Thawley SE, Panje WR, Batsakis JG, Lindberg RD, editors. Comprehensive management of head and neck tumors, vol. 1. Philadelphia: W.B. Saunders Co; 1987. p. 614-83.
2. Kieff E. Epstein-Barr virus-increasing evidence of a link to carcinoma. N Engl J Med 1995;333:724-6.
3. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;43:831-40.
4. Eliopoulos AG,Young LS. LMP1 structure and signal transduction. Semin Cancer Biol 2001;11:435-44.
5. Horikawa T, Yoshizaki T, Sheen TS, Lee SY, Furukawa M. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 2000;89:715-23.
6. Yoshizaki T, Horikawa T, Qing-chun R, et al. Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin Cancer Res 2001;7:1946-51.
7. Yoshizaki T, Sato H, Furukawa M, Pagano JS. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci U S A1998;95:3621-6.
8. Horikawa T,Yang J, Kondo S, et al.Twist and epithelial-mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metatstatic nasopharyngeal carcinoma. Cancer Res 2007;67:1970-8.
9. Kondo S,Wakisaka N, Schell MJ, et al. Epstein-Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding sit formed by a single nucleotide polymorphism: enhanced susceptibility to nasopharyngeal carcinoma. IntJ Cancer 2005;115:368-76.
10. Wakisaka N, Murono S,Yoshizaki T, Furukawa M, Pagano JS. Epstein-Barr virus latent membrane protein 1 induces and causes release of fibroblast growth factor-2. Cancer Res 2002;62:6337-44.
11. Murono S, Inoue H, Tanabe T, et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci U S A 2001;98: 6905-10.
12. Wakisaka N, Kondo S,Yoshizaki T, et al. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1. Mol Cell Biol 2004;24:5223-34.
13. Bucciarelli LG, Wendt T, Rong L, et al. RAGE is a mul-tiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease [review]. Cell Mol Life Sci 2002;59:1117-28.
14. Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor(RAGE) in the pathogenesis of diabetic microsngiopathy. Int J Clin Pharmacol Res 2003;23:129-34.
15. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 2000;275: 40096-105.
16. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-60.
17. Schraml P, Bendik I, Ludwig CU. Differential messenger RNA and protein expression of the receptor for advanced glycosylated end products in normal lung and non-small cell lung carcinoma. Cancer Res 1997;57:3669-71.
18. Kuniyasu H, Oue N,Wakikawa A, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002;196:163-70.
19. Sasahira T, Kirita T, Bhawal UK, et al. The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch 2007;450:287-95.
20. Kuniyasu H, Chihara Y, Kondo H, Ohmori H, Ukai R. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep 2003;10:1863-8.
21. Kuniyasu H, ChiharaY,Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 2003;10:445-8.
22. Kim W, Hudson BI, Moser B, et al. Receptor for advanced glycation end products and its ligands: a journey from the complications ofdiabetes to itspath-ogenesis. Ann N YAcad Sci 2005;1043:553-61.
23. Arumugam T, Simeone DM, Golen KV, Logsdon CD. S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res 2005;15:5356-64.
24. Shanmugaratnam K, Sobin LH. Histological typing of tumors of the upper respiratory tract and ear. In: World Health Organization International Histological Classification of Tumors. 2nd ed. Berlin: Springer;1991.p.32-4.
25. UICC. TNM classification of malignant tumours. In: Sobin LH, Wittekind Ch, editors. 5th ed. New York: Wiley-Liss; 1997.
26. Wakisaka N, Wen Q-H, Yoshizaki T, et al. Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma. Laryngoscope1999;109:810-4.
27. Yoshizaki T, Sato H, Murono S, Pagano JS, Furukawa M. Matrix metalloproteinase 9 is induced by the Epstein-Barr virus BZLF1 transactivator. Clin Exp Metastasis1999;17:431-6.
28. Vera-Sempere FJ, Micheau C, Llombart-Bosch A. S-100 protein positive cells in nasopharyngeal carcinoma (NPC): absence of prognostic significance. A clini-copathological and immunohistochemical study of 40 cases. Virchows Arch A Pathol Anat Hist 1987;411: 233-7.
29. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-α through nuclear factor-κ B, and by 17β-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000;275:25781-90.
30. Takimoto T, Furukawa M, Hatano M, Umeda R. Epstein-Barr virus nuclear antigen-positive nasopharyngeal hybridcells. Ann Otol Rhinol Laryngol 1984;93:166-9.
31. Yoshizaki T, Wakisaka N, Pagano JS. Epstein-Barr Virus, Invasion and metastasis, chapter 12. In: E. Robertson, editor. Epstein-Barr virus. Norfolk (United Kingdom): Caister Academic Press; 2005. p. 171-96.
32. Weidner N, Semple JP, Welch WR, et al.Tumorangio-genesis and metastases-correlation in invasive breast carcinoma. N Eng J Med1991;324:1-8.
33. Macchiarini P, Fontanini G, Hardin MJ, et al. Relation of neovascularization to metastasis of non-small-cell lung cancer. Lancet1992;340:145-6.
34. Yamagishi S, Yonekura H,YamamotoY, et al. Advanced glycation end products-driven angiogenesis in vitro: induction of growth and the formation of human microvascular endothelial cells through autocrine vascular endothelial cell growth factor. J Biol Chem 1997;272:8723-30.
35. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 2001;276:43836-41.
36. Nathanson SD. Insights into the mechanism of lymph node metastasis. Cancer 2003;98:413-23.
37. Tsai PW, Shiah SG, Lin MT, Wu CW, Kuo ML. Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-β1. A critical role of p38/nuclear factor-κB signaling pathway. J Biol Chem 2003;278:5750-9.
38. Takada M, Hirata K, Ajiki T, Suzuki Y, Kuroda Y. Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology 2004;51:928-30.